Skip to content
XPR
content.
Press releases
Video
Podcasts
Op-eds
Lists
Guest posts
Author:
Regentis Biomaterials Ltd
Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal
October 12, 2026
Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City
October 9, 2026
Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
September 11, 2026
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology
July 20, 2026
Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch
July 15, 2026
Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement
June 17, 2026
Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate
June 8, 2026